385 related articles for article (PubMed ID: 18533766)
21. Prolactin awareness: an essential consideration for physical health in schizophrenia.
Montejo AL
Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
[TBL] [Abstract][Full Text] [Related]
22. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
23. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Hummer M; Huber J
Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
[TBL] [Abstract][Full Text] [Related]
24. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
25. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
26. Adverse events in children and adolescents treated with antipsychotic medications.
Jerrell JM; McIntyre RS
Hum Psychopharmacol; 2008 Jun; 23(4):283-90. PubMed ID: 18302312
[TBL] [Abstract][Full Text] [Related]
27. Switching in the era of atypical antipsychotics. An updated review.
Weiden PJ
Postgrad Med; 2006 Sep; Spec No():27-44. PubMed ID: 17128659
[TBL] [Abstract][Full Text] [Related]
28. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
[TBL] [Abstract][Full Text] [Related]
29. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
McIntyre RS; Konarski JZ
J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
[TBL] [Abstract][Full Text] [Related]
30. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents.
Jerrell JM; Bacon J; Burgis JT; Menon S
J Adolesc Health; 2009 Jul; 45(1):70-6. PubMed ID: 19541252
[TBL] [Abstract][Full Text] [Related]
31. Metabolic side effects of atypical antipsychotics in children: a literature review.
Fedorowicz VJ; Fombonne E
J Psychopharmacol; 2005 Sep; 19(5):533-50. PubMed ID: 16166191
[TBL] [Abstract][Full Text] [Related]
32. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
33. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.
Correll CU; Kratochvil CJ; March JS
J Clin Psychiatry; 2011 May; 72(5):655-70. PubMed ID: 21658348
[TBL] [Abstract][Full Text] [Related]
34. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
Shirzadi AA; Ghaemi SN
Harv Rev Psychiatry; 2006; 14(3):152-64. PubMed ID: 16787887
[TBL] [Abstract][Full Text] [Related]
35. Side effects as influencers of treatment outcome.
Sharif Z
J Clin Psychiatry; 2008; 69 Suppl 3():38-43. PubMed ID: 18533761
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotic-induced hyperprolactinemia.
Bostwick JR; Guthrie SK; Ellingrod VL
Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
[TBL] [Abstract][Full Text] [Related]
37. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular risks of atypical antipsychotic drug treatment.
Drici MD; Priori S
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
Byerly M; Suppes T; Tran QV; Baker RA
J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
[TBL] [Abstract][Full Text] [Related]
40. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Miller LJ
Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
